Scholarlink

<p>Tumor nanovaccines have attracted great interest recently, due to a variety of advantages including high stability, efficient antigen packing and delivery, and the capacity to elicit sustained anti-tumor immune responses. Despite these advantages, existing nanovaccines are constrained by intricate manufacturing procedures and high production costs, prompting a need to develop simpler and more cost-effective solutions. In this study, we introduce a novel STING-activating tumor nanovaccine, designated OVA/Tp@Mn-DNA. The preparation of OVA/Tp@Mn-DNA nanovaccine is a straightforward process involving the self-assembly of Mn<sup>2+</sup> and DNA molecules into nanospheres, which are then crosslinked with both antigenic peptides and antigen-presenting cells (APC)-targeting peptides. Our findings reveal that the OVA/Tp@Mn-DNA nanovaccine facilitates the delivery of antigens to APCs, activates STING signaling pathway effectively and triggering robust cellular immune responses. Results from xenograft mouse tumor model demonstrate a remarkable therapeutic potential of OVA/Tp@Mn-DNA in combating tumors. Collectively, our work presents a new strategy offering OVA/Tp@Mn-DNA as an uncomplicated and economical nanovaccine for potent tumor immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A STING-activating biomimetic mineralized nanovaccine triggers robust anti-tumor immunity

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月7日

查看全文
  • Suxing Tuo,
  • Yihan Wang,
  • Meng Tian,
  • Lixia Su,
  • Jing Dong,
  • Kefeng Lv,
  • Wencan He,
  • Qing Feng,
  • Shan Chen,
  • Daozhu Dong,
  • Xiaoxu Li,
  • Kejun Zhong,
  • Yueming Zhang,
  • Bo Kong,
  • Lan He

摘要

Tumor nanovaccines have attracted great interest recently, due to a variety of advantages including high stability, efficient antigen packing and delivery, and the capacity to elicit sustained anti-tumor immune responses. Despite these advantages, existing nanovaccines are constrained by intricate manufacturing procedures and high production costs, prompting a need to develop simpler and more cost-effective solutions. In this study, we introduce a novel STING-activating tumor nanovaccine, designated OVA/Tp@Mn-DNA. The preparation of OVA/Tp@Mn-DNA nanovaccine is a straightforward process involving the self-assembly of Mn2+ and DNA molecules into nanospheres, which are then crosslinked with both antigenic peptides and antigen-presenting cells (APC)-targeting peptides. Our findings reveal that the OVA/Tp@Mn-DNA nanovaccine facilitates the delivery of antigens to APCs, activates STING signaling pathway effectively and triggering robust cellular immune responses. Results from xenograft mouse tumor model demonstrate a remarkable therapeutic potential of OVA/Tp@Mn-DNA in combating tumors. Collectively, our work presents a new strategy offering OVA/Tp@Mn-DNA as an uncomplicated and economical nanovaccine for potent tumor immunotherapy.